Cargando…
Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity
BACKGROUND: Obesity is a chronic disease associated with increased morbidity and mortality due to its complications. The aims of obesity treatment are primarily to accomplish weight loss, and prevention or treatment of its complications. Lifestyle changes along with behavioral therapy constitute the...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028372/ https://www.ncbi.nlm.nih.gov/pubmed/36349778 http://dx.doi.org/10.1159/000526808 |
_version_ | 1784909937267179520 |
---|---|
author | Yazıcı, Dilek Yapıcı Eser, Hale Kıyıcı, Sinem Sancak, Seda Sezer, Havva Uygur, Melin Yumuk, Volkan |
author_facet | Yazıcı, Dilek Yapıcı Eser, Hale Kıyıcı, Sinem Sancak, Seda Sezer, Havva Uygur, Melin Yumuk, Volkan |
author_sort | Yazıcı, Dilek |
collection | PubMed |
description | BACKGROUND: Obesity is a chronic disease associated with increased morbidity and mortality due to its complications. The aims of obesity treatment are primarily to accomplish weight loss, and prevention or treatment of its complications. Lifestyle changes along with behavioral therapy constitute the first-line treatment of obesity followed by pharmacotherapy. Glucagon-like peptide receptor analogs (GLP-1 RAs) are among the approved pharmacotherapy options. Their central effect on suppressing appetite results in considerable weight loss. However, their effect on the complications of obesity has not been very well recognized. This review aims to analyze the effects of GLP-1 RAs on the complications of obesity, as diabetes mellitus, hypertension, nonalcoholic steatohepatitis (NASH), cardiovascular diseases, polycystic ovary syndrome, infertility, obstructive sleep apnea (OSA), osteoarthritis, cancer and central nervous system problems. SUMMARY: Data from preclinical studies and clinical trials have been thoroughly evaluated. Effects regarding the complications as far as the scope of this review have covered can be summarized as blood glucose lowering, blood pressure lowering, resolution of NASH, improving major cardiovascular events, improving fertility and sex hormone levels, and improvement in OSA symptoms and in cognitive scores. Although the mechanisms are not fully elucidated, it is clear that the effects are not solely due to weight loss, but some pleiotropic effects like decreased inflammation, oxidative stress, and fibrosis also play a role in some of the complications. KEY MESSAGES: Treating obesity is not only enabling weight loss but ameliorating complications related to obesity. Thus, any antiobesity medication has to have some favorable effects on the complications. As far as the GLP-RA's analogs are concerned, there seems to be an improvement in many of the complications regardless of the weight loss effect of these medications. |
format | Online Article Text |
id | pubmed-10028372 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-100283722023-03-22 Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity Yazıcı, Dilek Yapıcı Eser, Hale Kıyıcı, Sinem Sancak, Seda Sezer, Havva Uygur, Melin Yumuk, Volkan Obes Facts Review Article BACKGROUND: Obesity is a chronic disease associated with increased morbidity and mortality due to its complications. The aims of obesity treatment are primarily to accomplish weight loss, and prevention or treatment of its complications. Lifestyle changes along with behavioral therapy constitute the first-line treatment of obesity followed by pharmacotherapy. Glucagon-like peptide receptor analogs (GLP-1 RAs) are among the approved pharmacotherapy options. Their central effect on suppressing appetite results in considerable weight loss. However, their effect on the complications of obesity has not been very well recognized. This review aims to analyze the effects of GLP-1 RAs on the complications of obesity, as diabetes mellitus, hypertension, nonalcoholic steatohepatitis (NASH), cardiovascular diseases, polycystic ovary syndrome, infertility, obstructive sleep apnea (OSA), osteoarthritis, cancer and central nervous system problems. SUMMARY: Data from preclinical studies and clinical trials have been thoroughly evaluated. Effects regarding the complications as far as the scope of this review have covered can be summarized as blood glucose lowering, blood pressure lowering, resolution of NASH, improving major cardiovascular events, improving fertility and sex hormone levels, and improvement in OSA symptoms and in cognitive scores. Although the mechanisms are not fully elucidated, it is clear that the effects are not solely due to weight loss, but some pleiotropic effects like decreased inflammation, oxidative stress, and fibrosis also play a role in some of the complications. KEY MESSAGES: Treating obesity is not only enabling weight loss but ameliorating complications related to obesity. Thus, any antiobesity medication has to have some favorable effects on the complications. As far as the GLP-RA's analogs are concerned, there seems to be an improvement in many of the complications regardless of the weight loss effect of these medications. S. Karger AG 2022-11-08 /pmc/articles/PMC10028372/ /pubmed/36349778 http://dx.doi.org/10.1159/000526808 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Review Article Yazıcı, Dilek Yapıcı Eser, Hale Kıyıcı, Sinem Sancak, Seda Sezer, Havva Uygur, Melin Yumuk, Volkan Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity |
title | Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity |
title_full | Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity |
title_fullStr | Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity |
title_full_unstemmed | Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity |
title_short | Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity |
title_sort | clinical impact of glucagon-like peptide-1 receptor analogs on the complications of obesity |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028372/ https://www.ncbi.nlm.nih.gov/pubmed/36349778 http://dx.doi.org/10.1159/000526808 |
work_keys_str_mv | AT yazıcıdilek clinicalimpactofglucagonlikepeptide1receptoranalogsonthecomplicationsofobesity AT yapıcıeserhale clinicalimpactofglucagonlikepeptide1receptoranalogsonthecomplicationsofobesity AT kıyıcısinem clinicalimpactofglucagonlikepeptide1receptoranalogsonthecomplicationsofobesity AT sancakseda clinicalimpactofglucagonlikepeptide1receptoranalogsonthecomplicationsofobesity AT sezerhavva clinicalimpactofglucagonlikepeptide1receptoranalogsonthecomplicationsofobesity AT uygurmelin clinicalimpactofglucagonlikepeptide1receptoranalogsonthecomplicationsofobesity AT yumukvolkan clinicalimpactofglucagonlikepeptide1receptoranalogsonthecomplicationsofobesity |